Here are the 10-Q quarterly reports from Generate Biomedicines, Inc. (GENB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow GENB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GENB filings page.
Generate Biomedicines, Inc. is an AI-driven, clinical-stage biotechnology company developing protein therapeutics on its Generate Platform. Collaboration revenue was $6,314 (in thousands) in Q2 2026 and $13,538 (in thousands) year-to-date, mainly from multi-program agreements with Novartis and Amgen.
Research and development expense reached $64,330 (in thousands) in the quarter and $122,142 (in thousands) for the first half, reflecting a Phase 3 program for GB-0895 in severe asthma, a Phase 1 trial for GB-4362, and preparations for a Phase 1 trial of GB-5267. Net loss attributable to common stockholders was $67,255 (in thousands) for Q2 and $136,450 (in thousands) for the first six months, with net cash used in operating activities of $138,332 (in thousands).
Following a March 2026 IPO that generated net proceeds of $369,289 (in thousands), cash, cash equivalents and marketable securities totaled $457.4 million at June 30, 2026, and stockholders’ equity was $456,045 (in thousands). Management states that existing capital is expected to fund the current operating plan into the first half of 2028.
Generate Biomedicines, Inc. reports first-quarter 2026 results as a newly public, clinical-stage biotech focused on AI-driven protein therapeutics. Collaboration revenue was $7.2 million, while operating expenses of $71.3 million led to a net loss of $61.7 million. Research and development spending rose to $57.8 million as the company advanced GB-0895 into Phase 3 severe asthma trials and prepared first-in-human studies for GB-4362 and GB-5267. Net cash used in operating activities was $80.4 million. After its IPO, which generated $369.3 million in net proceeds, cash, cash equivalents and marketable securities reached $516.6 million as of March 31, 2026, and management expects this to fund operations into the first half of 2028.